Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07502300 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)

StatusRecruiting
PhasePhase 3
Started2026-06-15
View on ClinicalTrials.gov ↗

Amendment history

2026-07-23
Study Status, Contacts/Locations v3
Recruitment opened
Start dateestimated 2026-04→confirmed 2026-06-15
Study sitesdetails revised at 2 of 2 sites
2026-04-15
Study Identification, Study Status v2
Study title+14 characters
[...] ment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
2026-04-09
Study Identification, Study Status v1
Study title+1 characters
[...] Treatment in Patients With Extensive-stage Small Cell Lung CanceCancer
2026-03-25
Original filing
This trial is a registrational Phase III, randomized, open-label, multicenter study to compare the efficacy and safety of BL-B01D1 in combination with tislelizumab versus platinum-based chemotherapy in combination with tislelizumab in first-line patients with extensive-stage small cell lung cancer.
Trial Details
NCT Number NCT07502300
Lead Sponsor Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Conditions Extensive-stage Small-cell Lung Cancer
Enrollment 562 participants
Start Date 2026-06-15
Primary Completion 2029-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-27